A New Spin-Off Dedicated to Aesthetics, While Strengthening Its Core Clinical Trial Imaging
January 1, 2026 Sophia Antipolis, France – QuantifiCare, a global leader in 2D/3D imaging solutions for clinical trials, is thrilled to announce the launch of Quartier Latin, a newly created spin-off fully dedicated to the aesthetic imaging market. With this evolution, QuantifiCare sharpens its core focus on imaging for clinical trials, while Quartier Latin will independently drive innovation and growth in aesthetics. This separation enables each company to concentrate on its respective strengths, deliver more specialized solutions, and better serve the distinct needs of its customers.
Founded with a mission to bring rigorous imaging technology to clinical research, QuantifiCare has grown to serve two complementary markets: pharmaceutical, biotech companies conducting clinical trials, and aesthetic practitioners seeking cutting-edge imaging tools for their daily practice. Over time, the synergy between these two activities fueled innovation and growth across both domains. As the company enters a new phase of expansion, the creation of two independent entities allows each business to sharpen its focus, pursue distinct investment strategies, and ensure sustainable long-term innovation.
QuantifiCare will continue to concentrate on its core business: providing advanced imaging services and system solutions for clinical trials across dermatology, aesthetics, wound care, and other therapeutic areas. Built on deep scientific expertise, regulatory compliance, and imaging standardization, QuantifiCare will remain a trusted partner to pharmaceutical, biotech, and CRO partners worldwide helping to optimize imaging needs and accelerating drug development. This evolution will also enable QuantifiCare to strengthen its collaboration and investments in artificial intelligence, driving the next generation of imaging analytics.
To more effectively address the rapidly evolving needs of the aesthetics market and to bring scientific rigor and technological innovation directly to aesthetic practices, Quartier Latin will assume responsibility for the sales, support, and continued development of the LifeViz® Neo portfolio, including 2D and 3D cameras and associated software solutions used by practitioners in more than 70 countries.
Quartier Latin will focus on streamlining workflows, leveraging Cloud capabilities, and driving automation, AI features to deliver intuitive, high-resolution imaging systems and innovative skin analysis tools for aesthetics. Quartier Latin aims to become the leading partner for aesthetic practitioners seeking to elevate their consultations and enhance the customer experience.
“This evolution enables each company to sharpen its focus and accelerate innovation in its respective field,” says Jean-Philippe Thirion, Founder and CEO of QuantifiCare. “By allowing QuantifiCare to concentrate on clinical trial imaging while Quartier Latin is fully dedicated to the aesthetic market, we are positioning both organizations for long-term growth and customer success.”
About QuantifiCare
QuantifiCare is a leading provider of imaging services for clinical trials in dermatology, aesthetics, and wound healing. With a global presence and a commitment to scientific rigor, QuantifiCare helps the pharmaceutical and biotech companies collect to collect, analyze high-quality, standardized imaging data for regulatory submissions for clinical trials. The company is actively advancing its artificial intelligence initiatives to enhance imaging analytics, automate evaluations, and deliver data-driven insights that accelerate clinical research.
About Quartier Latin
Quartier Latin is a company dedicated to advancing 3D imaging solutions for aesthetic professionals. Building on QuantifiCare’s heritage of scientific excellence, Quartier Latin offers the LifeViz® product line and related digital tools to enhance communication between aesthetic specialists and their customers, optimize outcomes, and elevate the standards of aesthetic consultations worldwide.
For more information, visit:
www.quantificare.com